Kałuiny Jakub J, Majer Anna, Jaworowska-Cieślińska Iwona
Klin Oczna. 2015;117(1):9-13.
To evaluate results of treatment of choroidal neovascularization due to age-related macular degeneration with aflibercept in a group of patients representative for Polish population.
Three intravitreal injections of 2.0 mg of aflibercept were administrated to 48 eyes with active choroidal neovascularization at the four week intervals. In the evaluated population there were 19 eyes previously treated with other anti-VEGF drugs and 29 treatment naive eyes.
The mean best corrected visual acuity at baseline in the entire group was 0.47. During the follow-up exam after the first injection, the best corrected visual acuity increased to 0.58. After the second and third injection, it reached the level of 0.62 and 0.63, respectively. Such improvement in visual acuity was accompanied by the reduction of central retinal thickness. Eyes with intraretinal fluid presence confirmed in baseline spectral domain optical coherence tomography had significantly lower best corrected visual acuity throughout the entire follow up.
Three intravitreal aflibercept injections in eyes with neovascular age-related macular degeneration resulted in significant improvement of best corrected visual acuity and reduction of central retinal thickness both in eyes previously treated using other anti-VEGF drugs and newly diagnosed ones. aflibercept, neovascular age-related macular degeneration, choroidal neovascularization, anti-VEGF treatment, optical coherence tomography.
在一组代表波兰人群的患者中评估阿柏西普治疗年龄相关性黄斑变性所致脉络膜新生血管的效果。
对48只患有活动性脉络膜新生血管的眼睛每隔四周进行三次玻璃体内注射2.0毫克阿柏西普。在评估人群中，有19只眼睛先前接受过其他抗VEGF药物治疗，29只眼睛为初治眼。
整个组在基线时的平均最佳矫正视力为0.47。在首次注射后的随访检查中，最佳矫正视力提高到0.58。在第二次和第三次注射后，分别达到0.62和0.63的水平。视力的这种改善伴随着视网膜中央厚度的降低。在基线光谱域光学相干断层扫描中确认存在视网膜内液的眼睛在整个随访过程中的最佳矫正视力明显较低。
对患有新生血管性年龄相关性黄斑变性的眼睛进行三次玻璃体内阿柏西普注射，在先前使用其他抗VEGF药物治疗的眼睛和新诊断的眼睛中均导致最佳矫正视力显著改善和视网膜中央厚度降低。阿柏西普、新生血管性年龄相关性黄斑变性、脉络膜新生血管、抗VEGF治疗、光学相干断层扫描。
